<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="radionuclide imaging, examples of saturable targets include beta-adrenergic, muscarinic and" exact="estrogen" post="receptors, which bind labeled analogues (Eckelman et al., 1979,"/>
 <result pre="Schuster, 2004). By bringing about the selective retention of phosphorylated" exact="acyclovir" post="and other thymidine analogues within infected cells, the HSV"/>
 <result pre="HIV pandemic, for example, FDG-PET was used to demonstrate that" exact="zidovudine" post="therapy had a beneficial effect in patients with HIV-related"/>
 <result pre="al., 2008). Although a study of the pharmacokinetics of 11C-labeled" exact="stavudine" post="in rats was based on measuring radioactivity in excised"/>
 <result pre="imaging. Examples include: â€¢a recombinant vaccinia virus encoding the human" exact="norepinephrine" post="transporter, which enables PET imaging by causing124I-meta-iodobenzylguanidine (MIBG) to"/>
 <result pre="been inoculated with a recombinant vaccinia virus encoding the human" exact="norepinephrine" post="transporter. The probe, 124I-MIBG, is taken up by the"/>
 <result pre="imaging reporter was first explored in the early 1980s, when" exact="acyclovir" post="was approved as an antiviral drug for the treatment"/>
 <result pre="the HSV TK is the basis of antiviral therapy with" exact="acyclovir" post="and other nucleoside analogues. Acyclovir enters cells from the"/>
 <result pre="the kidneys. In HSV-infected cells, however, the viral TK converts" exact="acyclovir" post="to its monophosphate, which is then converted by cellular"/>
 <result pre="genomes, causing chain termination (Elion, 1983). The selective retention of" exact="acyclovir" post="and related antivirals in HSV-infected cells and their rapid"/>
 <result pre="its UL97 protein kinase to phosphorylate nucleosides. Because UL97 recognizes" exact="acyclovir" post="to only a limited extent, the drug cannot be"/>
 <result pre="herpesvirus-induced cancers, such as Burkitt's lymphoma, with the anti-cancer drug" exact="bortezomib" post="triggers expression of the viral TK, making it possible"/>
 <result pre="tumors to be visualized by PET, but potentially treated with" exact="ganciclovir" post="(Fu et al., 2007). As noted above, poxviruses also"/>
 <result pre="gene, suggesting that their mechanism of action resembles that of" exact="acyclovir" post="(Prichard et al., 2007, Prichard et al., 2006). However,"/>
 <result pre="making them vulnerable to destruction by antibodies tagged with high-energy" exact="alpha" post="emitters (Dadachova et al., 2006). It has been suggested"/>
 <result pre="directly to virions to inhibit their replication are the adamantanes," exact="amantadine" post="and rimantidine, which block the M2 ion channel, preventing"/>
 <result pre="nature of this interaction suggests that small doses of radiolabeled" exact="amantadine" post="or rimantadine could be used to localize an influenza"/>
 <result pre="this interaction suggests that small doses of radiolabeled amantadine or" exact="rimantadine" post="could be used to localize an influenza virus infection"/>
 <result pre="exit cells has provided targets for antiviral therapy. The small-molecule" exact="ST-246" post="interacts specifically with the vaccinia virus F13L protein, which"/>
 <result pre="enveloped virions (Yang et al., 2005, Duraffour et al., 2008)." exact="ST-246" post="is nontoxic for mammalian cells, animals and humans, suggesting"/>
 <result pre="Opin. Biol. Ther.7200759559717477798 CassL.M.BrownJ.PickfordM.FayinkaS.NewmanS.P.JohanssonC.J.ByeA.Pharmacoscintigraphic evaluation of lung deposition of inhaled" exact="zanamivir" post="in healthy volunteersClin. Pharmacokinet.36Suppl. 11999213110429837 ChakrabartiB.K.MaitraR.K.MaX.Z.KestlerH.W.A candidate live inactivatable"/>
 <result pre="E2PLoS One42009e814219997645 ChenN.ZhangQ.YuY.A.StritzkerJ.BraderP.SchirbelA.SamnickS.SerganovaI.BlasbergR.FongY.SzalayA.A.A novel recombinant vaccinia virus expressing the human" exact="norepinephrine" post="transporter retains oncolytic potential and facilitates deep-tissue imagingMol. Med.15200914415119287510"/>
 <result pre="E2 glycoproteinsFEBS Lett.546200338539012832074 DuraffourS.VigneS.VermeireK.GarcelA.VanstreelsE.DaelemansD.YangG.JordanR.HrubyD.E.CranceJ.M.GarinD.AndreiG.SnoeckR.Specific targeting of the F13L protein by" exact="ST-246" post="affects orthopoxvirus production differentlyAntivir. Ther.13200897799019195323 EbiharaH.TheriaultS.NeumannG.AlimontiJ.B.GeisbertJ.B.HensleyL.E.GrosethA.JonesS.M.GeisbertT.W.KawaokaY.FeldmannH.In vitro and in"/>
 <result pre="tumors: estrogen-receptor interactions and selectivity of tissue uptake of halogenated" exact="estrogen" post="analogsJ. Nucl. Med.2119805505586247466 KlapperP.E.CleatorG.M.BruceJ.M.LongsonM.Penetration of the blood-brain barrier by"/>
 <result pre="of RNA virusesAntiviral Res.78200892518313769 LivniE.BerkerM.HillierS.WallerS.C.OganM.D.DiscordiaR.P.RienhartJ.K.RubinR.H.FischmanA.J.Preparation and pharmacokinetics of 11C labeled" exact="stavudine" post="(d4T)Nucl. Med. Biol.31200461362115219280 LomholtS.Pharmacology of bismuth, with reference to"/>
</results>
